EP3908282
TREATMENT OF CANCER HAVING GNAQ OR GNA11 GENETIC MUTATIONS WITH PROTEIN KINASE C INHIBITORS
:
EP einkaleyfi: EP einkaleyfi tilnefnt til gildistöku á Íslandi:
7.1.2020:
2.7.2025:
20703606.2
:
6.1.2040:
6.1.2026
:
TREATMENT OF CANCER HAVING GNAQ OR GNA11 GENETIC MUTATIONS WITH PROTEIN KINASE C INHIBITORS
7.1.2020
2.7.2025
6.1.2026
:
Ideaya Biosciences, Inc.:
5000 Shoreline Court, Suite 300, South San Francisco, CA 94080, US
:
KNOX, John:
Emerald Hills, CA 94062, US
:
LACKNER, Mark:
San Mateo, CA 94403, US
:
MOUNIR, Zineb:
Pacifica, CA 94044, US
:
O'BRIEN, Carol:
Brisbane, CA 94005, US
:
201962789177 P:
7.1.2019:
US
:
US2020012542:
7.1.2020
:
A61K 31/506, A61K 45/06, A61P 35/00